A case of neutropenia associated with cephapirin therapy is described. After discontinuation of cephapirin therapy, the neutrophil count returned to normal. Bone marrow examination revealed a marked reduction of polymorphonuclear leukocytes beyond the metamyelocyte stage and eosinophilia.
Cephapirin sodium is a new cephalosporin antibiotic for parenteral use. The in vitro antibacterial activity of this drug is equivalent to that of cephalothin (1, 4) . The major advantage of cephapirin in comparison to cephalothin appears to be the relatively low incidence of pain and phlebitis with intravenous administration (1, 4) .
The present report describes a patient in whom marked neutropenia developed during a 6-day course of treatment with cephapirin.
J. H., a 50-year-old black male, was admitted to the Hospital of the Medical College of Pennsylvania for evaluation of abdominal pain, nausea, and vomiting after a bout of ingestion of alcohol. Although a heavy drinker, he worked regularly and, on admission, the patient was a well-nourished muscular man who was not intoxicated. The rectal temperature was 101 F (37.7 C). Rales and diminished breath sounds were present over the right lower lung. The initial roentgenogram of the chest showed right lower and middle lobe pulmonary infiltrates. Gram stain of the sputum showed many neutrophils and gram-positive diplococci. Diplococcus pneumoniae was isolated from the sputum on culture and from the heart blood of a mouse which died within 24 hr after intraperitoneal inoculation with the sputum. Blood cultures were sterile. Two pretreatment total white-blood-cell counts performed less than 12 hr apart were 8,600 and 4,600/mm', of which 7,912 and 3,956/mm', respectively, were neutrophils. The latter count showed a marked shift to the left, with 3,128/mm' nonsegmented neutrophils.
The patient was treated with intramuscularly administered ceph-pirin sodium, in a dosage of 1 g every 6 hr for 6 days. He became afebrile within 24 hr, and the pulmonary consolidation cleared within 5 days after the start of cephapirin therapy. No other drugs were administered. On the day after discontinuation of the antibiotic, at which time the patient felt completely well, the total white-blood-cell count was There was no history of penicillin allergy or of previous treatment with a cephalosporin.
Depression of the bone marrow, at times leading to pancytopenia or aplastic anemia, can be a toxic reaction to a wide variety of drugs. The appearance during administration of cephapirin of profound neutropenia in this patient, who had one elevated and one normal total neutrophil count prior to therapy, and the subsequent rise in the numbers of neutrophils in the peripheral blood after the drug was discontinued suggest that the neutropenia was induced by cephapirin.
Pneumococcal pneumonia with concurrent folic acid deficiency (2) and alcoholic intoxication (6) are associated with neutropenia. However, the patient in this report had a normal total white-VOL. 1, 1972 blood-cell and differential counts without evidence of megaloblastic anemia on admission. Cephalothin, another cephalosporin antibiotic, has been reported to be rarely associated with neutropenia. In one report (3), three of approximately 300 patients treated with cephalothin developed transient neutropenia after 18 to 22 days of intramuscular treatment. Bone marrow examination in one of these patients, performed 2 days after discontinuation of cephalothin when the white blood cell and differential counts were normal, showed a "moderately cellular marrow with a shift to the left in the myeloid series with metamyelocytes predominating." These three patients developed splenomegaly, eosinophilia, fever, or skin rashes which suggested that the neutropenia was due to hypersensitivity. In another report (5), a reversible severe granulocytopenia was observed in two patients with high titers of anticephalothin antibodies which reacted with cephalothin-coated neutrophils in vitro and presumably caused destruction of coated cells in vivo.
The neutropenia in the patient in the present report is compatible with either toxic depression of myelopoiesis or excessive peripheral destruction of neutrophils related to antibodies directed against cephapirin-coated neutrophils. Although rash, fever, or splenomegaly did not develop, the eosinophilia in the bone marrow suggests a hypersensitivity reaction.
Of 46 patients studied thus far (1, 4), the patient in the present report was the only one who developed neutropenia after treatment with cephapirin. A personal communication from Bristol Laboratories indicates that this patient is the only one who was reported to have developed neutropenia in over 1,200 hospitalized patients treated with cephapirin. Further studies are necessary to determine the incidence of this toxic side effect in patients treated with cephapirin.
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